http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2002009788-A1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-486 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-48 |
| filingDate | 2001-06-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d870732dff3a8d39c5add05fcc488807 |
| publicationDate | 2002-01-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2002009788-A1 |
| titleOfInvention | Modulation of plasma membrane human leukocyte elastase |
| abstract | A method for modulation of plasma membrane associated Human Leukocyte Elastase (HLE) to inflammatory states by interaction of HLE with an antagonist to inhibit HLE and thereby interruption in plasma associated events (e.g. HIV disease progression, bacterial infections and autoimmune diseases), which are responsive/sensitive to such inflammation. The antagonist suitable for use in this invention is designed to interact with each of the catalytic triad of the HLE plasma membranes protein and the lipid interactive amino acids of the HLE plasma membrane protein. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2018310097-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006183214-A1 |
| priorityDate | 2000-07-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 47.